-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：Viatris公佈了2026年第一季穩健的業績，營收達35.17億美元（年成長8%），超出市場預期1.5億美元；調整後每股收益為0.59美元（年成長18%），超出市場預期0.09美元。調整後EBITDA年增14%至10.49億美元，顯示完成的策略評估帶來了顯著的營運槓桿效應。品牌產品組合表現強勁，淨銷售額達23億美元（年增10%），主要得益於大中華區（同比增長22%）的出色表現以及新興市場的持續強勁增長；而仿製藥銷售額則穩定在11.77億美元（同比增長5%）。儘管已將2月納西克工廠火災的影響納入考量，管理層仍重申了2026年的所有業績指引範圍，包括總營收144.5億美元至149.5億美元，調整後每股收益2.33美元至2.47美元。新產品開發進展順利，第一季營收7,100萬美元，朝著全年4.5億美元至5.5億美元的目標穩步邁進。我們認為，迄今為止，策略評估已成功推動第一季營運改進，並為Viatris的健康成長奠定了基礎。
Related Articles
Australia
CVS Health Increasingly Likely to Reach 3% Medicare Advantage Target Margin in 2028, RBC Says
CVS Health (CVS) is increasingly more likely to reach its 3% Medicare Advantage target margin in 2028, RBC Capital Markets analyst said in a note Wednesday.Analysts said the company's Q1 adjusted earnings "comfortably" beat expectations, driven by "strong" topline growth and a notable improvement in profitability in the Health Care Benefits segment.Medical costs came in below expectations and, while the company maintained its medical benefit ratio guidance for the year, it is increasingly likely to outperform, according to the note.The brokerage raised its 2026 adjusted earnings estimate for the company to $7.41 from $7.10. Analysts surveyed by FactSet expect $7.29.RBC reiterated its outperform rating on the stock and increased its price target to $107 from $93.Price: $87.01, Change: $+0.14, Percent Change: +0.17%
$CVS
Research
Research Alert: CFRA Maintains Strong Buy Rating On Shares Of Trimble Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target price to $86, from 85, on a forward P/E of 21x our 2027 EPS projection of $4.08, below historical averages. We increase our 2026 EPS projection to $3.59 from $3.52, and lift our 2027 EPS estimate to $4.08 from $4.06. TRMB reported solid Q1 beats with revenue of $939.9M, up 12% Y/Y, led by AECO at 14% organic revenue and ARR growth, Field Systems posting 12% growth, and Transportation & Logistics growing 7% despite freight market headwinds. ARR reached a record $2.435B, up 13% organically, reinforcing business model durability. Non-GAAP operating margin improved 230 bps to 25.9%, while non-GAAP gross margins expanded 180 bps to 71.0%, and we see continued margin expansion as its subscription revenues scale. We note steady execution in its core business, while building AI momentum through new products and partnerships with AI labs. Management reaffirmed its 2027 targets, supporting our positive view, though macro risks warrant monitoring.
$TRMB
Australia
Apollo Global Trades at Lower Discount Versus Peers, RBC Says
Apollo Global Management (APO) shares are trading in-line with historical average multiple and at a lower discount against its peers, RBC Capital Markets said in a Thursday note."We maintain our Sector Perform rating largely driven by relative valuation," the report said.The note said its Q1 performance was characterized by strong fee-related earnings growth, offset by weak spread-related earnings growth, driving a low adjusted net income per share growth.RBC raised its price target to $146 from $139 on rolling forward its valuation and higher estimates.Price: $127.33, Change: $-2.20, Percent Change: -1.70%
$APO